Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 16, 2021 09:00 ET | Source: CohBar, Inc.

CohBar Appoints Carol Nast to Its Board of Directors

MENLO PARK, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
August 10, 2021 16:04 ET | Source: CohBar, Inc.

CohBar Reports Second Quarter 2021 Financial Results and Provides Business Update

MENLO PARK, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
August 10, 2021 16:02 ET | Source: CohBar, Inc.

CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity

CB4211 was well-tolerated and appeared safe with no serious adverse eventsRobust reductions in ALT and AST Reduction in glucose and trend towards body weight reductionCompany to host conference call...
August 04, 2021 16:05 ET | Source: CohBar, Inc.

CohBar to Announce 2021 Second Quarter Financial Results and Provide Business Update on August 10, 2021

MENLO PARK, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
July 14, 2021 09:00 ET | Source: CohBar, Inc.

CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity

MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
June 10, 2021 09:00 ET | Source: CohBar, Inc.

CohBar to Present at the BIO 2021 Digital Conference

MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
May 17, 2021 16:02 ET | Source: CohBar, Inc.

CohBar Reports First Quarter 2021 Financial Results and Provides Business Update

MENLO PARK, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
May 03, 2021 09:00 ET | Source: CohBar, Inc.

CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021

MENLO PARK, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
April 27, 2021 08:30 ET | Source: CohBar, Inc.

CohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director

MENLO PARK, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
April 21, 2021 09:00 ET | Source: CohBar, Inc.

CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

MENLO PARK, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...